Feature-assisted interactive geometry reconstruction in 3D point clouds using incremental region growing

Reconstructing geometric shapes from point clouds is a common task that is often accomplished by experts manually modeling geometries in CAD-capable software. State-of-the-art workflows based on fully automatic geometry extraction are limited by point cloud density and memory constraints, and require pre- and post-processing by the user. In this work, we present a framework for interactive, user-driven, feature-assisted geometry reconstruction from arbitrarily sized point clouds. Based on seeded region-growing point cloud segmentation, the user interactively extracts planar pieces of geometry and utilizes contextual suggestions to point out plane surfaces, normal and tangential directions, and edges and corners. We implement a set of feature-assisted tools for high-precision modeling tasks in architecture and urban surveying scenarios, enabling instant-feedback interactive point cloud manipulation on large-scale data collected from real-world building interiors and facades. We evaluate our results through systematic measurement of the reconstruction accuracy, and interviews with domain experts who deploy our framework in a commercial setting and give both structured and subjective feedback.Comment: 13 pages, submitted to Computers & Graphics Journa

Adaptive pointcloud segmentation for assisted interactions

In this work, we propose an interaction-driven approach streamlined to support and improve a wide range of real-time 2D interaction metaphors for arbitrarily large pointclouds based on detected primitive shapes. Rather than performing shape detection as a costly pre-processing step on the entire point cloud at once, a user-controlled interaction determines the region that is to be segmented next. By keeping the size of the region and the number of points small, the algorithm produces meaningful results and therefore feedback on the local geometry within a fraction of a second. We can apply these finding for improved picking and selection metaphors in large point clouds, and propose further novel shape-assisted.</p

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to &lt; 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of &amp; GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P &lt; 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo